Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Advancements in the diagnosis and treatment of patients with prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 2094
Rating:

Prof Heather Payne, Prof Kurt Miller, Ms Netty Kinsella and Prof David Dearnaley

Professor Heather Payne chairs a discussion with Professor Kurt Miller, Ms Netty Kinsella and Professor David Dearnaley around advancements in the diagnosis and treatment of patients with prostate cancer.


Discussions around diagnosis highlighted the results of the PROMIS trial; with multiparametric MRI allowing more men with clinically insignificant disease to avoid biopsy. Active surveillance was also discussed as an important tool for the treatment of men with early or low risk disease.


Conversations around diagnosis for advanced disease focused around PSMA scanning which is perceived by the experts to have provided significant advancements in terms of specificity and sensitivity of diagnosis.


The group also discuss data around treatment of oligometastatic disease and the potential use of biomarkers and next generation sequencing in precision medicine, as well as the use of chemotherapy and abiraterone in combination with ADT as a promising treatment for patients with castration sensitive disease.
Looking to the future of treatment of patients with prostate cancer, the experts discuss the treatment of locally advanced disease and the use of abiraterone and docetaxel in this patient group. The importance of further understanding optimal combinations of treatment modalities for individual patients is also highlighted.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation